<DOC>
	<DOCNO>NCT01905527</DOCNO>
	<brief_summary>This Phase IV study compare current level MS LifeLines ® ( MSLL ) service ( face-to-face nursing visit phone contact ) customize MSLL service , determine optimal service enhance medication adherence treatment persistence Rebif ® subcutaneous three time week .</brief_summary>
	<brief_title>Adherence Trial With MS LifeLines ® Services</brief_title>
	<detailed_description>The propose study web-based , prospective , parallel group , Phase IV , 12-month study patient receive support service provide MSLL contract nursing service . Following referral patient MSLL , consent patient allocate one two group ( 2:1 ) , base geographic area . Group A randomize 1:1 standard service subgroup ( Group A1 ) customize service subgroup ( Group A2 ) . The standard subgroup receive phone call nurse visit set interval . Patients custom service subgroup option select many `` standard '' service receive initial injection training . Subjects option receive educational material , planning tool , reminder . Patients allocate Group B receive visit injection train follow-up call MSLL phone call set interval . Over period 12 month ( month define 28-day period ) , subject receive support service ( nurse visit follow-up phone call , etc ) complete online assessment ( MSRS-R , PDSS , etc ) . The primary objective trial determine impact two different level support service , group A1 A2 , provide MSLL within Group A , adherence prescribe treatment newly diagnose first-switch relapse remit multiple sclerosis ( RRMS ) subject . Secondary Objective : The secondary objective : - To use pair wise comparison determine impact adherence two different level service intervention provide MSLL compare primary objective ( Standard service subgroup Group A ( A1 ) Group B Customized service subgroup Group A ( A2 ) Group B ) - To determine correlation adherence subject-reported outcome study data ; - To examine change baseline subject-reported outcome service arm ; - To examine change baseline risk non-adherence service arm ; - To determine rate trial dropout service arm</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<criteria>Age 18 65 year time inform consent signature Male female Female subject child bear potential report pregnant screen agree avoid pregnancy study participation use adequate contraception , define two barrier method , one barrier method spermicide , intrauterine device , use oral female contraceptive Outpatient status time online screen Subjects prescribe Rebif treat physician first diseasemodifying drug ( DMD ) receive , one prior treatment either Rebif , Copaxone ® , Avonex ® , Extavia ® , Betaseron ® , Gilenya™ , Aubagio ® ( accelerate elimination ) , Tysabri ® Tecfidera™ Access , ability use , computer , mouse , internet , email address . In addition , subject Group A required access telephone accepts text messaging ( case randomize Custom subgroup ) Subjectreported ability complete online assignment read English Electronically verify informed consent trialrelated activity carry Any combination therapy another DMD Multiple Sclerosis ( MS ) participate trial Score 4 item MSRSR score 5 8 , inclusive , PDDS Surgical intervention plan 12month study period Pregnant breastfeeding . Note subject 90 day postpartum , stable , breastfeed may participate . History malignancy , exception skin cancer completely excise consider cured ; History seizure unexplained blackout within 30 day prior online screen Current illegal drug use time online screening ; Any prior participation interventional clinical trial MS ( except Aubagio ® Tecfidera™ ) , participation trial within 30 day prior online screen , current participation another clinical trial ; Current treatment another autoimmune disorder stable thyroid disease time online screen History prior treatment MS following : alemtuzumab , cyclophosphamide , methotrexate , azathioprine , cyclosporin , intravenous immunoglobulin ( IVIg ) , plasma exchange Other significant subjectreported disease would exclude subject trial Significant renal hepatic impairment would compromise completion trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Relapsing-Remitting</keyword>
	<keyword>Rebif</keyword>
	<keyword>Quintiles Geographic Area Group</keyword>
	<keyword>Standard Subgroup</keyword>
	<keyword>Custom Subgroup</keyword>
	<keyword>RxCrossroads Geographic Area Group</keyword>
</DOC>